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Alopecia areata (AA) is characterized by hair loss in 
patches (patchy AA), over the entire scalp (AT, totalis), 
or universally (AU). An autoimmune mechanism has 
been hypothesized, because the inflammatory infil-
trate targeted to the hair follicles includes activated T 
cells. To investigate whether or not genetic polymor-
phism of the human leukocyte antigen (HLA) region 
contributes to disease susceptibility, we used sequence-
specific oligonucleotides and amplified genomic DNA 
to define HLA-DQA1, -DQB1, and -DPBl alleles in a 
cohort of 85 white patients. The frequency of 
DQB1*0301 was significantly increased to 41% in all 
patients, and to 47% in AT/AU patients relative to con-
trols (27%). Analyzed together, DQB1*03 alleles 
(DQB1*0301-*0303) were increased to 80% (all pa-
tients) and to 92% (AT/AU) (odds ratio = 12.14, P = 
0.00003, corrected). This striking association im-
Alopecia arcata (AA) is a common disease of unknown etiology affecting approximately 1.0% of the popula-tion. It ranges in severity from self-limited, small foci of hair loss to persistent, total elimination of all hair [1] . Potentially reversible, it is characterized by either 
limited patchy hair loss (alopecia areata, patchy AA), loss of all scalp 
hair (alopecia totalis, AT), or loss of all body hair (alopecia universa-
lis, AU) . AA has been suggested to be an autoimmune disease or an 
immunologically mediated disease because it is associated with 
other autoimmune disorders (2) and because there is an inflamma-
tory infiltrate of activated Tcells surrounding the hair follicles [1 ,3). 
Human leukocyte antigen (HLA) class II expression is seen on fol-
licular keratinocytes in biopsy specimens from AA patients [4-6]. 
However, this ectopic expression ofHLA class II may be secondary 
to the T-cell infiltrate and indicative of cell injury [7]. The anti-
gen(s) involved and the antigenic specificity of the lymphocytic 
infiltrate in the AA process are currently unknown. 
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plicates the DQB1*03 alleles in the pathogenesis of AA. 
DQB1*06 was decreased relative to controls (56%) in 
all patients (32%, odds ratio = 0.37, P = 0.0045, 
corrected). An increase was observed in the HLA-
DRB1*11(DR5) allele DRB1*1104, which may result 
from linkage disequilibrium with DQBl alleles. Se-
quence comparison among the allele products asso-
ciated with AA indicates that the DQB1*03 alleles 
carry a unique proline at position 55 that is not present 
in alleles that are neutral or negatively associated with 
the disease. This highly significant association may 
exert considerable control over immune responsive-
ness and the initiation or persistence of a T-cell au-
toimmune response against the hair follicle. Key words: 
autoimmunity/hair/T cells/HLA disease association. ] In-
vest Dermato1103:758-763, 1994 
Like many other autoimmune diseases [8), AA shows significant 
genetic association with particular alleles of the class II human 
major histocompatibility complex (MHC). This region on chromo-
some 6 encodes the highly polymorphic DR, DQ, and DP ap he-
terodimers present on antigen-presenting cell s of the immune sys-
tem [9). AA has been associated weakly with increased genotypic 
frequencies of HLA-DR4 and DR5(DRBl*11) in whites [10-12), 
and with a significant decrease in DRw52a (DRB3*0101) [10]. 
Odum et al [13] also reported HLA-DPB1 associations with AA. 
Morling et al [14] have reported a 4.2-kb BgllI restriction fragment 
length polymorphism (RFLP) (associated with HLA-DQB1 * 0301) 
in a small study of 20 Danish AA patients. 
Because HLA class II molecules dictate the T-cell repertoire and 
exert considerable control over immune responsiveness [15] , efforts 
to understand the role of HLA class II genes in disease susceptibility 
have focused on the detailed characterization of alleles from healthy 
and diseased individuals using serologic, cellular, and RFLP typing 
methods. Previous reports of HLA associations with AA have not 
used the more accurate typing method of hybridization of allele-
specific oligonucleotide probes on amplified genomic DNA and 
have been too small to be of statistical significance. In our efforts to 
understand the contribution of HLA genes to susceptibility or re-
sistance to patchy AA and AT/AU, we have used this powerful 
technique to type HLA-DQA1, -DQB1, and -DPB1 alleles in a 
large white American AA patient population. In addition, by this 
method we subtyped allelic variants in 38 DR4- and 23 
DR5(DRB1*11)-positive AA patients to determine whether the 
finding of an increased frequency of HLA-DR4 in three separate 
studies and HLA-DR5 in two separate studies may be due to an 
association with one of the subtypes of DR4 or DR5 or due to 
linkage disequilibrium with another HLA-D-region gene. 
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Table I. Oligonucleotide Sequences for Polymerase Chain Reaction Amplification 
Left Right 
HLA-DRBl 
HLA-DR4 
HLA-DR5(11) 
HLA-DPBl 
HLA-DQAl 
HLA-DQBl 
5' GGAGCAGGTT AAACATGAG 3' 5' CCGCTGCACTGTGAAGCTCT 3' 
5' GTTTCTTGGAGCAGGTT AAAC 3' 
5'CACGTTTCTTGGAGTACTCTAC3' 
5' GAGAGTGGCGCCTCCGCTCAT 3' 
5' ATGGTGT AAACTTGTACCAGT 3' 
5' CATGTGCTACTTCACCAACGG 3' 
5' CCGCTGCACTGTGAAGCTCT 3' 
5' CCGCTGCACTGTGAAGCTCT 3' 
5' GCCGGCCCAAAGCCCTCACTC 3' 
5' TTGGTAGCAGCCGGTAGAGTTG 3' 
5'CTGGTAGTTGTGTCTGCACAC3' 
MATERIALS AND METHODS 
subjects After informed consent was obtained. 20 cm3 of heparinized 
blood was collected by venipuncture from 200 randomly selected. healthy 
local white volunteers of predominantly northwest European ancestry. Pa-
tients included 85 unrelated white individuals of similar ancestry with AA 
(patchy AA. n = 47). AT. or AU (AT/AU. ~ = 38). C~ntrolswerescre~ned 
for a history of AA or other autOimmune diseases. Patients were exammed 
and biopsied. and a diagnosis of patchy AA. AT. or AU was confirmed by a 
dermatologist. 
Preparation of Genomic DNA Genomic DNA from peripheral blood 
was prepared from buffy coat lymphocytes by p~oteinase-K/sodi~l~ d~de­
cylsulfate digestion. followed by phenol extraction. ethanol precIpitation. 
and storage in Tris-ethylenediaminetetraacetic acid. pH 7.4. at 4 · C [16]. 
Dot-Blot Analysis HLA-DRB1. -DQA1. and -DQBl loci from ge-
nomic DNA were amplified ill vitro by the polymerase chain reaction tech-
nique using TAQ polymerase (Cetus. Em~ryville, C!"-) an~ a therm~cycler 
(Perkin-Elmer-Cetus. Norwalk. CT) at 94 C.X 1 mm,60. C X 2 mm, and 
72°C X 3 min for 30 cycles. The DPBl lOCI were amphfied m the same 
manner at 94·C X 1 min, 61·C X 2 min, and 72·C X 3 min. The ampli-
fied DNA was dot blotted onto Zetabind membranes (Cuno, Meridian, CT) 
and hybridized with 32P-Iabeled allele-specific or sequence-specific oligonu-
cleotide (550) probes at 54·C. Probes were end-labeled with [i'2P]d-ATP 
using T4 polynucleotide kinase (Promega, Madison, WI) and were added to 
give no less than 1 X 106 cpm per ml of hybridization fluid. The hybrid.iza-
tion buffer was 50 mM Tns-HCI (pH 8.0), 2 mM EDTA. 0.1% sodIUm 
dodecyl sulfate, and 5 X Denhardt's solution, containing 100 tlg/ml her-
ring sperm DNA and 3.0 M tetramethyl ammonium chloride .. The mem-
branes were washed to a stringency of 2 X SSPE m buffer contammg tetra-
methyl ammonium chloride and exposed to Kodak XAR-5 film at -70· C, 
as described by the Eleventh International HLA Workshop. 
Oligonucleotide Primers and Probes . Oli~onucleotide 'primers 
(Table I) for polymerase chain reaction ampitficatlon of genonllc I?NA 
w ere synthesized using a Beckman desk-top syntheSizer and punfied usmg a 
Milligen/ Biosearch oligonucleotide purification column (Millipore, 
Burlington, MA). SSO probes obtained from the Eleventh International 
HLA Workshop were used to discriminate further between alleles of 
HLA-DR4 [DRB1·0401(Dw4), ·0402(Dwl0), ·0403(Dw13.1). 
·0404(Dw14.1). · 0405(Dw15), ·0406('KT2'). · 0407(Dw13.2). and 
·0408(Dw14.2)]; between four alleles of HLA-DRB1·11 (DR5) 
[DRB1·II01, ·1102, · 1103, and ·1104]; between 19 of the alleles 
that comprise the HLA-DPBl locus [·0101(DPwl), ·0201(DPw2), 
· 0202(DPw2). ·0301(DPw3), ·0401 (DPw4), ·0402(DPw4), 
·0501 (DPw5), ·0601 (DPw6). ·0801, ·0901(DP'Cp63), · 1001. · 1101 , 
·1301, ·1401, ·1501, ·1601, ·1701, ·1801, and ·1901]; between nine a1-
lelesofDQAl [· 0101, ·0102, ·0103, ·0201, -03 (·03011 . ·0302), ·03012, 
·0401, ·0501, and ·0601]; and between 15 alleles that comprise the DQBl 
specificities [·0201, ·0301, · 0302, · 0303(· 03031. ·03032), ·0401 . · 0402, 
·0501, ·0502. ·0503 (·05031, ·05032), · 0504, ·0601 . ·0602, · 0603, 
·0604. and ·0605]. In this report. allelic designations are used when appro-
priate, with the previous designations for HLA-DR. HLA-DQ, or HLA-DP 
specificities given in parentheses. 
Statistical Analysis Comparison of HLA specificities and allelic fre-
quencies in patients with AA or AT/AU versus normal race-matched con-
trols was performed using the x: analysis of 2 X 2 tables and Yate's correc-
tion with the EPI-INFO statistical program. If five or fewer persons were 
present per group, Fisher's exact two-tailed test was used. The p values were 
corrected for multiple comparisons, i.e., HLA-DQA 1. P value X nine alleles 
tested, unless otherwise noted. If an association had been reported previ-
ously, the p value was not corrected. Based on previous observations, the a 
priori hypothesis included that HLA-DR4, DRB1·11 (DR5), DQ7 
(DQB1·0301), and DPw4 alleles might be associated positively with AA. 
Odds ratios (OR) or relative risks and exact confidence levels were deter-
mined from the 2 X 2 tables. 
RESULTS 
Increased Frequency of HLA-DQB1*03 Alleles in AA Pa-
tients DQBl alleles were defined by amplification of the DQBl 
Table n. HLA-DQBl Frequencies in AA Patients and White Controls 
AA/AT/AU Patchy AA AT/AU Normal 
(n = 85) (n=47) (n = 38) (n = 200) 
Frequency Frequency Frequency Frequency 
HLA-DQBl % (n) p OR % (n) p OR % (n) p OR % (n) 
·0201 25% (21) 21 % (10) 29% (11) 36% (72) 
DQB1·03 80% (68) 0.00003 4.16 70% (33) >0.05 2.45 92% (35) 0.00003 12.14 49% (98) 
·0301 41 % (35) 0.026' 1.89 36% (17) 47% (18) 0.021' 2.43 27% (54) 
·0302 25% (21) 21 % (10) 29% (11) 17% (34) 
·0303 14% (12) >0.05 3.12 13% (6) 16% (6) >0.05 3.56 5% (10) 
·0401 0% (0) 0% (0) 0% (0) 0% (0) 
·0402 7% (6) 9% (4) 5% (2) 7% (14) 
·0501 25% (21) 32% (15) 16% (6) 29% (58) 
·0502 12% (10) 0.015 6.53 11% (5) >0.05 5.83 13% (5) > 0.05 7.42 2% (4) 
·0503 2% (2) 2% (1) 3% (1) 4% (8) 
·0504 0% (0) 0% (0) 0% (0) 0% (0) 
DQB1·06 32% (27) 0.004 0.37 36% (17) > 0.05 0.45 26% (10) 0.015 0.28 56% (112) 
· 0601 5% (4) 4% (2) 5% (2) 3% (5) 
·0602 21% (18) 23% (11) 18% (7) 26% (52) 
· 0603 2% (2) 0.03 .012 2% (1) 3% (1) 17% (33) 
· 0604 4% (3) 6% (3) 0% 11 % (22) 
·0605 0% (0) 0% (0) 0% 0 
• p uncorrected. based on previously documented association (Morling of 01 [14]). For all others. the p value is corrected by multiplying by the number of alleles tested (15 a.lleles). 
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Table III. HLA-DQAl Frequencies in White AA P atients" 
AA/ AT/AU Patchy AA AT/AU Normal 
(n= 47) (n = 23) (n =24) (n = 200) 
Frequency Frequency Frequency Frequcncy 
HLA·OQAl % (n) % (n) %(n) % (n) 
'0101 30% (14) 39% (9) 21% (5) 33% (66) 
'0102 38% (18) 39% (9) 38% (9) 37% (73) 
'0103 4% (2) 9% (2) 0% (0) 18% (35) 
'0201 21% (10) 9% (2) 33% (8) 20% (40) 
'03 40% (19)1 30% (7) 50% (12)' 25% (50) 
'0301 0% (0) 0% (0) 0% (0) 6% (12) 
'0401 13% (6) 17% (4) 8% (2) 6% (1 2) 
'0501 38% (18) 38% (9) 38% (9) 36% (71) 
'0601 2% (1) 0% (0) 4% (1) 1% (2) 
• p values are corrected (nine alleles tested). 
b p > 0.05, OR = 2.04. 
, P > 0.05, OR = 3.0. 
locus in 85 white patients, followed by hybridization with SSO 
probes (Table II). A significantly increased frequency of 
DQB1 *0301 was observed in this group of patients (41 % compared 
to 27% in controls, p = 0.026, uncorrected). In addition, the fre-
quency of the combined DQBl *03 alleles (*0301- *0303) was sig-
nificantly increased (80% compared to 49% in controls, p = 
0.00003, corrected). In the subgroup of severe AT/AU patients, the 
frequency of DQB*0301 was increased to 47%, compared to 27% 
in normal white controls (p = 0.021, uncorrected). Most striking, 
an increased frequency of the combined DQB1'03 alleles (92% 
compared to 49% in controls, p = 0.00003, corrected) was signifi-
cantly associated with the AT/AU phenotype. An increase in the 
frequency of the DQB 1 *0502 allele was significantly associated 
with disease when all patients were combined (12% compared to 
2% in controls, p = 0.015, corrected) . 
We also observed alleles that were reduced in AA patients. A 
significant decrease in the frequency of the HLA-DQBl *0603 al-
lele was observed in AA/ AT/AU patients (2% compared to 17% in 
controls, p = 0.03, corrected). In addition, a decrease in the com-
bined DQB 1 *06(*0601- '0605) alleles was signilicantly associated 
with the severe AT/AU phenotype (26% compared to 56% in con-
trols, p = 0.015, corrected). The decreased frequency of the 
DQB1*06 alleles was also significant for the total patient group 
(32% versus 56% in controls, p = 0.004, corrected). 
Analysis of the HLA-DQAl alleles from the 47 white patients 
examined in this study identified an insignificant increase in the 
frequency of the DQA 1*03 allele and a decrease in the frequency of 
the DQA1 *0103 allele in all patients (Table III). The frequency of 
the DQAl *0501 allele in this patient cohort was not increased, as 
reported previously by Morling et al (14) using RFLP typing. 
To address this question further, we analyzed the role of the 
combined presence of DQB1'0301 and DQA1*OSOl in the patient 
group versus controls (Table IV). When patients and normal white 
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controls who possessed the DQA 1*0501 allele were analyzed for • 
the combined presence ofDQB1*0301 and DQA1*0501, the OR • 
was significantly increased in the patients (OR = 8.06, P = 0.007, 
uncorrected). One hundred percent of AT/AU patients who pos-
sessed the DQA1*0501 allele also had the DQB1 *0301 allele, and 
80% of the AT/AU patients who carried the DQB1*0301 allele 
also had the DQA1 *0501 allele (OR = 2.89, P = 0.046). When • 
ana lyzed together, 33% of all patients typed for HLA-DQB1 and 
-DQA1 alleles carried the DQB*0301/DQA*OS01 combination, 
compared to 17% of controls (OR = 2.44, P = 0.027) . 
HLA-DPBl Alleles Are Not Associated With AA A report 
finding increased numbers of patients with HLA-DPw4 in AA [13] 
led us to perform HLA-DPB1 typing of 84 AA patients and 62 
normal white controls. In this study, we were able to subtype the ' 
HLA-DPB1 *04 (DPw4) into DPB1 *0401 and *0402 alleles. The 
other DPB 1 epitopes were defined according to the Eleventh 1nter- l 
national HLA Workshop. Amplified genomic DNA hybridized 
with SSO probes was used to define the HLA-DPB 1 alleles (Table 
V). The phenotypic frequencies of the DPB1 *0401 and *0402 al-
leles in all patients were 58% and 25%, respectively, and are similar 
to the control frequencies of 69% and 27%. The frequency of the 
DPB1*0101 allele was decreased, but not significantly, in both 
patchy AA and AT/AU patients versus controls (8% versus 18%, 
respectively). All other HLA-DPB1 alleles were similar to control 
frequencies, suggesting that in this group of patients, HLA-DPB1 
alleles are not associated with AA' 
HLA-DRB1 Alleles Associated with AA Eighty-eight white 
AA patients had been HLA-DR-typed previously using RFLP 
techniques (10) . Sixty-one percent of the patients had either HLA-
DR4 or DRBl *11 (DRS), compared with 40% of white controls. 
To define alleles that may be involved in disease susceptibility, we 
performed subtyping of AA patients with either HLA-DR4 or 
DRB1 *11 (DRS) specificities. Group-specific primers were used to 
amplify the DRB1*11 (DRS) region of genomic DNA, which then 
was hybridized with seven SSO probes to define four DRB1*11 
(DRS) alleles: HLA-DRB1*1101, *1 102, *1103, and *1104. Six of 
the seven DRB1*11 (DRS)-positive patchy AAratients were of 
the DRB1*1104 subtype (86%), versus 27% 0 the DRBI *11 
(DRS) white controls (OR = 16.25, P = 0.034, corrected). When 
all patchy AA and AT/AU patients were analyzed together, 
DRB1*1104 was found in 11 of 20 patients tested (55%), com-
pared with the frequency of DRB1 *1104 in normal HLA-
DRB1*11(DR5)-positive controls (27%) (Table VI). 
HLA-DR4 subtyping by generic or group-specific amplification 
of genomic DNA and hybridization with allele-specific oligonucle-
otide or SSO probes was used to define the HLA-DR4 alleles in 38 
HLA-DR4-positive AA patients. Allelic frequencies were not sig-
nificantly different from HLA-DR4 control frequencies (data not 
shown). Therefore, these resu' ts do not define a significant associa-
tion between any subtype of I LA· . R4 and AA. 
Table IV. Frequency (%) and OR for the Allelic Combination ofHLA-DQBl-0301 and HLA-DQA1*0501 in AAa 
AA/AT/AU Patchy AA 
OR 
Patients Frequency p (RRI) Frcquency 
All 33% 0.027 2.44 29% 
(14/43) (1.74) (6/21) 
OQB'0301- posi tive 82% > 0.05 86% 
(14/17) (6/7) 
OQA 1'0501- positive 88% 0.007 8.06 75% 
(14/16) (1.88) (6/8) 
' p values arc uncorrected based on previously documented association (Marling el al [14]). 
b RR, relative risk. 
'NO, not done. 
p 
> 0.05 
> 0.05 
> 0.05 
AT/AU 
OR OR Normal 
(RR) Frequency p (RR) Frequency 
36% > 0.05 17% 
(8/22) (33/200) 
80% 0.046 2.89 61% 
(8/10) (2.20) (33/54) 
100% 0.005 NO' 46% 
(8/8) (2.20) (33/71) 
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Table V. Frequency ofHLA-DPB1 Alleles Defined by 
Hybridization of Amplified DNA With SSO Probes in 
Healthy White and AA Patients 
HLA-DPBl 
A lleles' 
*0101 
*0201 
*0202 
*0301 
*0401 
*0402 
*0501 
*0601 
*0901 
*1001 
*1101 
*1401 
*1501 
Patchy AA 
(n = 36) 
8% (3) 
22% (8) 
0% (0) 
11% (4) 
69% (25) 
4% (5) 
6% (2) 
8% (3) 
8% (3) 
11%(4) 
3% (1) 
8% (3) 
6% (2) 
AT/AU 
(11 = 48) 
8% (4) 
31% (15) 
10% (5) 
15% (7) 
50% (24) 
33% (16) 
8% (4) 
2% (1) 
0% (0) 
0% (0) 
13% (6) 
2% (1) 
0% (0) 
All 
(11 = 84) 
8% (7) 
27% (23) 
6% (5) 
13% (11) 
58% (49) 
25% (21) 
7% (6) 
5% (4) 
4% (3) 
5% (4) 
8% (7) 
5% (4) 
2% (2) 
Controls 
(n = 62) 
18% (11) 
23% (1 4) 
2% (1) 
18% (11) 
69% (43) 
27%(17) 
5% (3) 
3% (2) 
3% (2) 
2% (1) 
8% (5) 
5% (3) 
2% (1) 
• The phenotypic and genotypic frequencies of the remaining DPB1 alleles, -0801, 
*1301, -1601 , -1701, -1801, and -1901, were less than or equal to 5% in all groups 
tested (patchy AA, AT, AA/AT, and white controls). 
DISCUSSIO N 
This study strongly implicates DQBl *03 alleles in the pathogenesis 
of AA. Although weak HLA class II associations, including DR4 
and DRB1*11(DR5), have been reported previously for AA [10-
12,17], serologic or RFLP HLA typing methods were used. DNA 
RFLPs associated with DQB1*0301 and DQA1*0501 were re-
ported in 20 Danish AA pa~ients. However, this was a very small 
study limited to one population [14]. It IS Important to note that the 
investigators did not analyze the severe AT/AU patients separately 
from the less severe patchy AA patients. In addition, RFLP typing 
cannot unequivocally identify critical polymorphic HLA alleles, 
which can be identified by the methods employed in our study. The 
goal of this study was to determine whether genetic polymorI?hisms 
of the HLA region contribute to disease susceptlblhty or resistance 
in AA. Using allele-specific or sequence-specific oligonucleotide 
probes, we provide a molecular analysis of HLA-DQA1, -DQB1, 
DRB1, and -DPBl all eles that may be important in the pathogene-
sis of AA and define previously unreported HLA aIIelic associations 
with AA. 
The expression of HLA-DQBl alleles in AA patients is not ran-
dom and shows a highly significant association ofDQB1*03 alleles. 
Ninety-two percent of AT/AU patients carried one of the closely 
related allelic variants, HLA-DQBl *0301, *0302, and *0303. The 
difference between these three alleles is limited to polymorphic 
residues at positions 13,26,45, and 57 of the DQBl gene product. 
Sequence comparison shows that only the amino acid at position 55 
of the DQ beta chain is unique in the sequences of the DQB1*03 
alleles, compared with all other DQB 1 alleles. All of the DQB 1*03 
alleles positively associated with AA/ AT/AU have proline at posi-
tion 55. Arginine or leucine is present at position 55 in all alleles that 
are neutral or negatively associated with disease (Table VII). 
E lucidation of the structure and function of major histocompati-
bility molecules has provided a molecular basis for HLA associations 
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with disease [1 8-20]. Critical polymorphic amino acid residues 
confer differences in peptide binding and ultimately in antigen pre-
sentation to T cell s, and may contribute to susceptibility to autoim-
mune diseases [21,22]. Recent resolution of the three-dimensional 
structure of the class II HLA-DR 1 molecule has allowed correlation 
of these polymorphic sites with functional regions of the molecule 
[20]. Based on the class II HLA-DRl structure, the polymorphic 
residue at position 55 of the DQ beta chain does not appear to be a 
direct peptide contact site. However, the unique proline at position 
55 of the DQ beta chain that is associated with AA/ AT/AU may 
have subtle effects on other residues involved in peptide binding, 
which would change the conformation of the peptide-binding 
groove. 
Human HLA-DR and -DQ molecules are expressed on the cell 
surface as afJ heterod imers. In ctystal forms of HLA-DR1, a dimer 
of class II afJ heterodimers has been observed. Although it is possible 
that dimer formation is a crystaIJization artifact, it has been hypoth-
esized to be involved in intracellular signaling events [20]. Residues 
whose side chains are in the dimer interface include positions 52 and 
55 of the beta chain. Using the class II HLA-DRl structure as a 
model for HLA-DQB1*03 alleles, aJIelic products with side chains 
of proline at position fJ 55 would be incapable of forming a salt 
bridge at the dimer interface. Therefore, in addition to a possible 
effect on the peptide-binding groove, polymorphism at position 55 
may affect the stability or structure of any dimer formation of afJ 
heterodimers. 
Genotyping for HLA-DQBl genes in these patients also showed 
an increase in the frequency of the DQB1 *0502 allele, which may 
result in an increased risk to develop AA or persistent disease. The 
DQBl *0502 aUele overrepresented in the patient population 
carries a unique serine residue at position 57 of the DQ beta chain. 
Because it is predicted to reside on the floor of the peptide-binding 
site, this may affect peptide class II interactions. The only other 
allelic product of the HLA-DQBl locus that possesses a serine resi-
due at position 57 , DQB 1 *0504, was not identified in the patient or 
control population. 
In this study, we were unable to confirm a proposed association of 
HLA-DQAl *0501 with disease [1 4]. However, the frequency of 
the combined presence of DQA1*0501 and DQB 1*0301 was sig-
l~ificantly increased over controls, confirming this previously pub-
hshed report. These results may suggest that an additive or synergis-
tic effect exists between DQB 1*0301 and DQA1*0501 alleles. 
Family studies will determine whether DQA1 *0501 and 
DQB1*0301 reside on the same chromosome ill these patients. In 
addition, we could not confirm an association between the serologi-
caUy defined DPBl *04(w4) and AA as reported for a Danish popu-
lation [13] . Sub typing of the DPBl *04(w4) alleles, DPBl *0401 
and *0402, which was not done in the previous study, showed no 
increase in either allele in these AA patients. Similar results were 
obtained when we analyzed the combined frequency of 
DPB1*0401 and *0402 alleles. 
Although associations between HLA-DQ and -DR with AA have 
been reported, the results have been controversial. Our previous 
studies used conventional RFLP techniques and showed an increase 
in the frequencies of HLA-DQw8(w3) alleles (found on DR4 hap-
lotypes) in all patients [10]. HLA-DQw7(w3) was not significantly 
increased; however, the number of heterozygotes with DQw7(w3) 
Table VI. Frequency (%) of Alleles HLA-DRB1*11 (DRS) in AA 
Patchy AA AT/AU All 
HLA-DRB*11(DR5) Alleles (n = 7) (n = 13) (n = 20) 
ORBI *1101 
DRB1*1102 
ORlll*1103 
DRB1*1104 
14% (1) 
0% (0) 
0% (0) 
86% (6)b 
54% (7) 
8% (1) 
0% (0) 
38% (5) 
40% (8) 
5% (1) 
0% (0) 
55% (1) 
.. One homozygous control. 
• p = 0.008, uncorrected two-tailed Fisher's exact test; p = 0.032 (X four alleles tested) versus white controls. OR = 16.25. 
White Controls' 
(n = 26) 
50% (13) 
15% (4) 
8% (2) 
27% (7) 
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Table VII. Conserved Region of Sequence Polymorphism in HLA-DQBl Alleles Expressed in AA Patients 
DQB1 Allele 50 51 
Disease associated 
301 V T 
302 V T 
303 V T 
Neutral or negative disease associated 
501 V T 
503 V T 
504 V T 
601 V T 
602 V T 
603 V T 
604 V T 
605 V T 
201 V T 
401 V T 
402 V T 
and DQw8(w3) was increased relative to controls. In several re-
ports using serologic or RFLP techniques, the frequency of 
DRB1"11(DR5) was increased. However, these studies used small 
cohorts and could not distinguish among allelic variants of the 
DRB1"11 (DRS) family [10-12,17] . The data reported here sug-
gest that the increased frequency observed for DRB1"11(DR5) may 
result from an increased number of patients with the HLA-
DRB1"11 (DRS) allele, DRB1"1104. This association with 
DRB1"1104 may result from linkage disequilibrium with 
DQB 1"03 alleles. It is unlikely that the increased frequency ob-
served in our patient population could be due to differences in 
the ethnicity ' of our patients versus controls. The 25 white 
DRB1"11 (DR5)-positive controls were split equally among 
northwestern and eastern European ancestry, whereas the AA pa-
tients were predominantly of northwestern European descent. Be-
cause the DRB1*1104 allele is found more frequently in eastern 
Europeans, the opposite result would have been predicted based on 
ethnicity alone [23] . 
DQB 1 *03 alleles associated with persistent disease (AT/AU) 
have a relative risk (OR) of 12.14. The OR associated with 
DRB1 *1104 for patchy AA is 16.25. Associations of HLA class II 
and other autoimmune diseases have been quantified in terms of 
relative risk [24]. For example, the relative risk associated with 
HLA-DR4 for insulin-dependent diabetes mellitus is 4 - 6; for 
HLA-DR3 and -DR7 associated with Celiac disease, reported rela-
tive risks are 8 -12; for HLA-DR4, w6 associated with pemphigus 
vulgaris, the relative risk has been reported to be as high as 24. 
Compared to previously reported relative risks for HLA-associated 
diseases, the relative risks for DQB 1 *03 alleles associated with se-
vere AT/AU and for DRB1 *1104 associated with patchy AA are 
profound. 
Our results suggest the possibility that more than one HLA allele 
can influence susceptibility to AA, or possibly result in persistence of 
the disease once triggered. It is not surprising that all patients with 
alopecia areata do not have the same allele. The presence of disease 
in individuals of differing HLA types could be explained by gene 
conversion-like events, which shuffle the hypervariable segments 
among different alleles [25 - 28]. This model is supported by studies 
of rheumatoid arthritis, associated with HLA-DR4 (DRB1 *0401, 
*0404/8, *0405) and DR1(*0101) [29,30], and of insulin-depen-
dent diabetes mellitus, associated with DR3 and DR4 [31]. Our 
results describing three closely related, disease-linked allelic var-
iants, HLA-DQB1 *0301, *0302, and *0303, which share a unique 
amino a.cid residue at position 55, also support this model of gene 
conversIOn. 
Alternatively, there could be different susceptibility epitopes, 
perhaps on different loci or on different chromosomes, that contrib-
AA Position 
52 53 54 55 56 57 
P L G P P D 
P L G P P A 
P L G P P D 
p Q G R P V 
P Q G R P D 
P Q G R P S 
P Q G R P D 
P Q G R P D 
P Q G R P D 
P Q G R P V 
P Q G R P V 
L L G L P A 
P L G R L D 
P L G R L D 
ute to disease pathogenesis. This model would explain the HLA 
association of DQB 1 *03 alleles and the DQB 1"0502 allele with 
disease, as well as reported IgG heavy-chain associations with AA 
[32]. 
The fact that certain major histocompatibility complex polymor-
phisms predispose an individual to aberrant immune responses lead-
ing to a disease state may provide insights about the underlying 
pathogenesis of AA. Further analysis of the role of these residue(s) in 
the immune response of AA may provide information about specific 
pathogenic antigens that might be bound by the disease-linked 
HLA polymorphisms. Much progress has been made in identifying 
class II sequences that confer susceptibility or resistance to many 
autoimmune diseases. However, our understanding of how HLA 
molecules function in disease development remains unclear. Per-
haps, in addition to the results presented here, studies examining 
autoreactive T cells from AA patients, candidate autoantigens, or 
virally induced immune reactions in AA will provide important 
clues about the role of HLA molecules in the pathogenesis and 
persistence of patchy AA, AT, and AU. 
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